Provided by Tiger Fintech (Singapore) Pte. Ltd.

Design Therapeutics, Inc.

5.05
-0.2100-3.99%
Volume:35.80K
Turnover:181.85K
Market Cap:287.59M
PE:-4.51
High:5.24
Open:5.24
Low:4.98
Close:5.26
52wk High:7.77
52wk Low:2.60
Shares:56.95M
Float Shares:26.28M
Volume Ratio:0.28
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1191
EPS(LYR):-0.8763
ROE:-26.77%
ROA:-19.02%
PB:1.35
PE(LYR):-5.76

Loading ...

Press Release: Design Therapeutics Highlights Momentum Across Lead GeneTAC(R) Programs and Reports First Quarter 2025 Financial Results

Dow Jones
·
May 08

Design Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
May 02

Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'

MT Newswires Live
·
May 02

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

GlobeNewswire
·
May 01

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

GlobeNewswire
·
Apr 22

Design Therapeutics Names Chris Storgard as Chief Medical Officer

MT Newswires Live
·
Apr 17

Press Release: Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Dow Jones
·
Apr 17

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

GlobeNewswire
·
Apr 17

Top Premarket Gainers

MT Newswires Live
·
Apr 02

RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Mar 11

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

Benzinga
·
Mar 10

BRIEF-Design Therapeutics Q4 Basic EPS USD -0.24

Reuters
·
Mar 10

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
Mar 10

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

GlobeNewswire
·
Mar 03